In vitro drug resistance versus chemosensitivity: Two sides of different coins

被引：17

作者：

Fruehauf, JP ^{[1
]}

Alberts, DS

机构：

[1] Univ Calif Irvine, Irvine, CA 92717 USA

[2] Chao Family Comprehens Canc Ctr, Orange, CA USA

[3] Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 15期

关键词：

D O I：

10.1200/JCO.2005.05.281

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3641 / 3643

页数：3

共 18 条

[1]

ALBERTS DS, 1980, LANCET, V2, P340

[2] Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay [J].

Bosanquet, AG ;

Johnson, SA ;

Richards, SM .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (01) :71-77

[3]

Brown E, 1996, CANCER, V77, P1020, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1020::AID-CNCR3>3.0.CO

[4]

2-L

[5]

Chu E, 2001, CANC PRINCIPLES PRAC, P289

[6]

CLARK GM, 1984, HUMAN TUMOR CLONING, P255

[7] Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer [J].

Cortazar, P ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1625-1631

[8] In vitro assay-assisted treatment selection for women with breast or ovarian cancer [J].

Fruehauf, JP .

[9]

FRUEHAUF JP, 1993, PRINCIPLES PRACTICE, V7, P1

[10] Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients [J].

Holloway, RW ;

Mehta, RS ;

Finkler, NJ ;

Li, KT ;

McLaren, CE ;

Parker, RJ ;

Fruehauf, JP .

GYNECOLOGIC ONCOLOGY, 2002, 87 (01) :8-16

← 1 2 →